30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Janux Therapeutics Inc (JANX)

Track

Over the last 90 days, Janux Therapeutics Inc. has seen net insider selling totaling $858,221. All transactions were sales, with no insider purchases recorded. Notably, several executives and officers, including the Chief Corp. & Bus. Dev. Officer and Vice President of Accounting, have made sales. The company's stock has experienced a slight decline of 2.3% over the same period.
Stock chart
Ticker: JANX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Doyle Janeen Noel
Chief Corp. & Bus. Dev. Ofcr
1 sale — total 56,944 USD
Sale 2 Jun 2026
Value US$544,254.91 | Price 419.39 | Shares 82,767
Proposed sale 2 Jun 2026
Value US$1,117,229.82 | Price 135.82 | Shares 29,115
Sale 11 May 2026
Value US$28,878.46 | Price 14.17 | Shares 2,038
Proposed sale 13 Apr 2026
Value US$28,245.66 | Price 15.05 | Shares 1,877
Proposed sale 2 Apr 2026
Value US$1,095,760.52 | Price 14.65 | Shares 74,802
Proposed sale 26 Jan 2026
Value US$2,601,113.48 | Price 14.55 | Shares 178,767
Proposed sale 23 Jan 2026
Value US$1,738,389.66 | Price 14.72 | Shares 118,122
Sale 2 Jan 2026
Value US$37,263.22 | Price 13.73 | Shares 2,714
Planned sale 2 Jan 2026
Value US$34,393.65 | Price 13.73 | Shares 2,505
Sale 2 Jan 2026
Value US$110,828.56 | Price 13.73 | Shares 8,072
Planned sale 2 Jan 2026
Value US$20,073.26 | Price 13.73 | Shares 1,462
Planned sale 2 Jan 2026
Value US$32,965.73 | Price 13.73 | Shares 2,401
Sale 2 Jan 2026
Value US$25,798.67 | Price 13.73 | Shares 1,879
Proposed sale 15 Dec 2025
Value US$258,366.33 | Price 15.50 | Shares 16,666
Proposed sale 8 Dec 2025
Value US$826,000.00 | Price 16.52 | Shares 50,000
Proposed sale 2 Dec 2025
Value US$1,033,743.00 | Price 16.38 | Shares 63,125
Planned sale 1 Dec 2025
Value US$21,221.14 | Price 33.52 | Shares 633
Planned sale 1 Dec 2025
Value US$88,707.96 | Price 32.85 | Shares 2,700
Proposed sale 1 Dec 2025
Value US$113,621.97 | Price 34.09 | Shares 3,333
Proposed sale 14 Nov 2025
Value US$91,524.18 | Price 27.46 | Shares 3,333
Planned sale 14 Nov 2025
Value US$99,990.00 | Price 30.00 | Shares 3,333
Planned sale 28 Oct 2025
Value US$500,986.56 | Price 30.06 | Shares 16,665
Proposed sale 28 Oct 2025
Value US$455,787.75 | Price 27.35 | Shares 16,665
Planned sale 1 May 2025
Value US$13,041.36 | Price 32.60 | Shares 400
Planned sale 1 May 2025
Value US$93,703.19 | Price 31.95 | Shares 2,933
Proposed sale 1 May 2025
Value US$110,655.60 | Price 33.20 | Shares 3,333
Planned sale 21 Apr 2025
Value US$100,020.00 | Price 30.00 | Shares 3,334
Proposed sale 21 Apr 2025
Value US$98,986.46 | Price 29.69 | Shares 3,334
Buy 7 Mar 2025
Value US$3,418,590.12 | Price 31.02 | Shares 110,206
Buy 6 Mar 2025
Value US$11,453,022.54 | Price 30.78 | Shares 372,093
Buy 5 Mar 2025
Value US$1,172,341.50 | Price 31.30 | Shares 37,455
Buy 5 Mar 2025
Value US$9,299,010.72 | Price 30.56 | Shares 304,287
Planned sale 3 Mar 2025
Value US$29,598.66 | Price 32.85 | Shares 901
Planned sale 3 Mar 2025
Value US$77,575.72 | Price 31.88 | Shares 2,433
Proposed sale 3 Mar 2025
Value US$109,655.26 | Price 32.89 | Shares 3,334
Planned sale 3 Feb 2025
Value US$4,360.00 | Price 43.60 | Shares 100
Planned sale 3 Feb 2025
Value US$34,900.56 | Price 42.77 | Shares 816
Planned sale 3 Feb 2025
Value US$101,738.80 | Price 42.08 | Shares 2,418
Proposed sale 3 Feb 2025
Value US$144,962.32 | Price 43.48 | Shares 3,334
Planned sale 7 Jan 2025
Value US$300,004.00 | Price 60.00 | Shares 5,000
Proposed sale 7 Jan 2025
Value US$300,004.00 | Price 60.00 | Shares 5,000
Planned sale 2 Jan 2025
Value US$11,473.00 | Price 57.37 | Shares 200
Planned sale 2 Jan 2025
Value US$56,777.80 | Price 56.78 | Shares 1,000
Planned sale 2 Jan 2025
Value US$192,032.96 | Price 55.76 | Shares 3,444
Planned sale 2 Jan 2025
Value US$314,420.02 | Price 54.51 | Shares 5,768
Planned sale 2 Jan 2025
Value US$157,081.46 | Price 53.76 | Shares 2,922
Proposed sale 2 Jan 2025
Value US$713,902.36 | Price 53.54 | Shares 13,334
Proposed sale 26 Dec 2024
Value US$1,404,805.00 | Price 56.19 | Shares 25,000
Planned sale 24 Dec 2024
Value US$1,404,805.00 | Price 56.19 | Shares 25,000
Planned sale 3 Dec 2024
Value US$1,005,000.00 | Price 67.00 | Shares 15,000
Planned sale 25 Nov 2024
Value US$349,646.68 | Price 52.04 | Shares 6,719
Planned sale 25 Nov 2024
Value US$940,232.05 | Price 51.43 | Shares 18,281
Proposed sale 1 Nov 2024
Value US$277,986.95 | Price 53.44 | Shares 5,202
Proposed sale 1 Nov 2024
Value US$158,909.99 | Price 52.99 | Shares 2,999
Proposed sale 1 Nov 2024
Value US$60,722.73 | Price 53.31 | Shares 1,139
Proposed sale 1 Nov 2024
Value US$3,028,665.39 | Price 53.66 | Shares 56,440
Proposed sale 1 Nov 2024
Value US$3,092,361.96 | Price 53.66 | Shares 57,627
Proposed sale 1 Nov 2024
Value US$586,731.20 | Price 53.66 | Shares 10,934
Planned sale 28 Oct 2024
Value US$598,909.14 | Price 53.94 | Shares 11,103
Planned sale 28 Oct 2024
Value US$739,649.76 | Price 53.22 | Shares 13,897
Proposed sale 28 Oct 2024
Value US$807,666.02 | Price 53.41 | Shares 15,122
Proposed sale 28 Oct 2024
Value US$483,519.81 | Price 53.36 | Shares 9,061
Proposed sale 28 Oct 2024
Value US$182,954.07 | Price 53.51 | Shares 3,419
Proposed sale 25 Oct 2024
Value US$9,029,543.55 | Price 53.33 | Shares 169,320
Proposed sale 25 Oct 2024
Value US$1,749,161.78 | Price 53.33 | Shares 32,800
Proposed sale 25 Oct 2024
Value US$9,219,392.35 | Price 53.33 | Shares 172,880
Proposed sale 24 Oct 2024
Value US$1,148,928.00 | Price 52.80 | Shares 21,760
Proposed sale 24 Oct 2024
Value US$1,148,928.00 | Price 5.28 | Shares 217,690
Proposed sale 24 Oct 2024
Value US$262,653.18 | Price 53.37 | Shares 4,921
Proposed sale 23 Oct 2024
Value US$12,745,011.15 | Price 51.23 | Shares 248,797
Proposed sale 23 Oct 2024
Value US$2,418,041.01 | Price 51.23 | Shares 47,203
Proposed sale 23 Oct 2024
Value US$12,482,474.96 | Price 51.23 | Shares 243,672
Proposed sale 23 Oct 2024
Value US$665,093.96 | Price 51.01 | Shares 13,039
Proposed sale 21 Oct 2024
Value US$532,309.72 | Price 49.43 | Shares 10,769
Proposed sale 21 Oct 2024
Value US$120,454.08 | Price 49.49 | Shares 2,434
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-04 2026-06-02 S Sale
Doyle Janeen Noel

Chief Corp. & Bus. Dev. Ofcr

Officer
82,767 +1.4%
419.39
US$544,255 		82,767 +1.4% 419.39 US$544,255
2026-06-02 2026-06-02 PrS Proposed sale
Janeen Noel Doyle

Officer

Officer
29,115
135.82
US$1,117,230 		29,115 135.82 US$1,117,230
2026-05-13 2026-05-11 S Sale
Dobek Maria

Vice President, Accounting

Officer
35,290 +2.4%
369.51
US$961,076 		35,290 +2.4% 369.51 US$961,076
2026-04-13 2026-04-13 PrS Proposed sale
1.8
ANDY MEYER

Former Affiliate
1,877
15.05
US$28,246 		1,877 15.05 US$28,246
2026-04-02 2026-04-02 PrS Proposed sale
1.0
ZACHARIAH A MCIVER

Former Officer

Officer
74,802
14.65
US$1,095,761 		74,802 14.65 US$1,095,761
2026-01-26 2026-01-26 PrS Proposed sale
1.8
ANDY MEYER

Former Affiliate
178,767
14.55
US$2,601,113 		178,767 14.55 US$2,601,113
2026-01-23 2026-01-23 PrS Proposed sale
1.8
ANDY MEYER

Former Affiliate
118,122
14.72
US$1,738,390 		118,122 14.72 US$1,738,390
2026-01-02 2026-01-02 S Sale
1.0
McIver Zachariah

Chief Medical Officer

Officer
2,714 -10.4%
13.73
US$37,263 		2,714 -10.4% 13.73 US$37,263
2026-01-02 2026-01-02 PlS Planned sale
DiRaimondo Thomas

Chief Scientific Officer

Officer
2,505 -2.0%
13.73
US$34,394 		2,505 -2.0% 13.73 US$34,394
2026-01-02 2026-01-02 S Sale
1.0
Campbell David Alan

President and CEO

Executive Director
8,072 -2.8%
13.73
US$110,829 		8,072 -2.8% 13.73 US$110,829
2026-01-02 2026-01-02 PlS Planned sale
Dobek Maria

Vice President, Accounting

Officer
1,462 -8.7%
13.73
US$20,073 		1,462 -8.7% 13.73 US$20,073
2026-01-02 2026-01-02 PlS Planned sale
Winter Charles M.

Chief Technical Officer

Officer
2,401 -3.0%
13.73
US$32,966 		2,401 -3.0% 13.73 US$32,966
2026-01-02 2026-01-02 S Sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
1,879 -2.2%
13.73
US$25,799 		1,879 -2.2% 13.73 US$25,799
2025-12-15 2025-12-15 PrS Proposed sale
BYRON C ROBINSON

Officer

Officer
16,666
15.50
US$258,366 		16,666 15.50 US$258,366
2025-12-08 2025-12-08 PrS Proposed sale
BYRON C ROBINSON

Officer

Officer
50,000
16.52
US$826,000 		50,000 16.52 US$826,000
2025-12-02 2025-12-02 PrS Proposed sale
BYRON C ROBINSON

Officer

Officer
63,125
16.38
US$1,033,743 		63,125 16.38 US$1,033,743
2025-12-03 2025-12-01 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
633 -0.7%
33.52
US$21,221 		633 -0.7% 33.52 US$21,221
2025-12-03 2025-12-01 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
2,700 -3.1%
32.85
US$88,708 		2,700 -3.1% 32.85 US$88,708
2025-12-01 2025-12-01 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
3,333
34.09
US$113,622 		3,333 34.09 US$113,622
2025-11-14 2025-11-14 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
3,333
27.46
US$91,524 		3,333 27.46 US$91,524
2025-11-14 2025-11-14 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
3,333 -3.8%
30.00
US$99,990 		3,333 -3.8% 30.00 US$99,990
2025-10-30 2025-10-28 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
16,665 -16.9%
30.06
US$500,987 		16,665 -16.9% 30.06 US$500,987
2025-10-28 2025-10-28 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
16,665
27.35
US$455,788 		16,665 27.35 US$455,788
2025-05-02 2025-05-01 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
400 -0.5%
32.60
US$13,041 		400 -0.5% 32.60 US$13,041
2025-05-02 2025-05-01 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
2,933 -3.4%
31.95
US$93,703 		2,933 -3.4% 31.95 US$93,703
2025-05-01 2025-05-01 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
3,333
33.20
US$110,656 		3,333 33.20 US$110,656
2025-04-23 2025-04-21 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
3,334 -3.9%
30.00
US$100,020 		3,334 -3.9% 30.00 US$100,020
2025-04-21 2025-04-21 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
3,334
29.69
US$98,986 		3,334 29.69 US$98,986
2025-03-07 2025-03-07 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
110,206 +1.1%
31.02
US$3,418,590 		110,206 +1.1% 31.02 US$3,418,590
2025-03-07 2025-03-06 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
372,093 +3.9%
30.78
US$11,453,023 		372,093 +3.9% 30.78 US$11,453,023
2025-03-07 2025-03-05 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
37,455 +0.4%
31.30
US$1,172,342 		37,455 +0.4% 31.30 US$1,172,342
2025-03-07 2025-03-05 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
304,287 +3.3%
30.56
US$9,299,011 		304,287 +3.3% 30.56 US$9,299,011
2025-03-05 2025-03-03 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
901 -1.1%
32.85
US$29,599 		901 -1.1% 32.85 US$29,599
2025-03-05 2025-03-03 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
2,433 -2.8%
31.88
US$77,576 		2,433 -2.8% 31.88 US$77,576
2025-03-03 2025-03-03 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
3,334
32.89
US$109,655 		3,334 32.89 US$109,655
2025-02-05 2025-02-03 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
100 -0.1%
43.60
US$4,360 		100 -0.1% 43.60 US$4,360
2025-02-05 2025-02-03 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
816 -1.0%
42.77
US$34,901 		816 -1.0% 42.77 US$34,901
2025-02-05 2025-02-03 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
2,418 -2.8%
42.08
US$101,739 		2,418 -2.8% 42.08 US$101,739
2025-02-03 2025-02-03 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
3,334
43.48
US$144,962 		3,334 43.48 US$144,962
2025-01-08 2025-01-07 PlS Planned sale
1.0
Campbell David Alan

President and CEO

Executive Director
5,000 -1.7%
60.00
US$300,004 		5,000 -1.7% 60.00 US$300,004
2025-01-07 2025-01-07 PrS Proposed sale
1.0
Campbell David Alan

Officer

Officer
5,000
60.00
US$300,004 		5,000 60.00 US$300,004
2025-01-03 2025-01-02 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
200 -0.2%
57.37
US$11,473 		200 -0.2% 57.37 US$11,473
2025-01-03 2025-01-02 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
1,000 -1.2%
56.78
US$56,778 		1,000 -1.2% 56.78 US$56,778
2025-01-03 2025-01-02 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
3,444 -4.0%
55.76
US$192,033 		3,444 -4.0% 55.76 US$192,033
2025-01-03 2025-01-02 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
5,768 -6.2%
54.51
US$314,420 		5,768 -6.2% 54.51 US$314,420
2025-01-03 2025-01-02 PlS Planned sale
1.8
Meyer Andrew Hollman

Chief Business Officer

Officer
2,922 -3.1%
53.76
US$157,081 		2,922 -3.1% 53.76 US$157,081
2025-01-02 2025-01-02 PrS Proposed sale
1.8
ANDREW MEYER

Officer

Officer
13,334
53.54
US$713,902 		13,334 53.54 US$713,902
2024-12-26 2024-12-26 PrS Proposed sale
1.0
Campbell David Alan

Officer

Officer
25,000
56.19
US$1,404,805 		25,000 56.19 US$1,404,805
2024-12-27 2024-12-24 PlS Planned sale
1.0
Campbell David Alan

President and CEO

Executive Director
25,000 -10.3%
56.19
US$1,404,805 		25,000 -10.3% 56.19 US$1,404,805
2024-12-03 2024-12-03 PlS Planned sale
1.0
Campbell David Alan

President and CEO

Executive Director
15,000 -5.8%
67.00
US$1,005,000 		15,000 -5.8% 67.00 US$1,005,000
2024-11-27 2024-11-25 PlS Planned sale
1.0
Campbell David Alan

President and CEO

Executive Director
6,719 -2.5%
52.04
US$349,647 		6,719 -2.5% 52.04 US$349,647
2024-11-27 2024-11-25 PlS Planned sale
1.0
Campbell David Alan

President and CEO

Executive Director
18,281 -6.5%
51.43
US$940,232 		18,281 -6.5% 51.43 US$940,232
2024-11-01 2024-11-01 PrS Proposed sale
3.9
Reardon Tighe

FORMER OFFICER

Officer
5,202
53.44
US$277,987 		5,202 53.44 US$277,987
2024-11-01 2024-11-01 PrS Proposed sale
4.0
Lichter Jay

FORMER DIRECTOR

Non-Executive Director
1,139
53.31
US$60,723 		1,139 53.31 US$60,723
2024-11-01 2024-11-01 PrS Proposed sale
3.9
Avalon Ventures XI, L.P.

10% Stockholder

Large shareholder
56,440
53.66
US$3,028,665 		56,440 53.66 US$3,028,665
2024-11-01 2024-11-01 PrS Proposed sale
Avalon BioVentures SPV I, L.P.

10% Stockholder

Large shareholder
57,627
53.66
US$3,092,362 		57,627 53.66 US$3,092,362
2024-11-01 2024-11-01 PrS Proposed sale
Avalon BioVentures I, LP

10% Stockholder

Large shareholder
10,934
53.66
US$586,731 		10,934 53.66 US$586,731
2024-11-01 2024-11-01 PrS Proposed sale
3.9
Reardon Tighe

Former officer

Officer
2,999
52.99
US$158,910 		2,999 52.99 US$158,910
2024-10-30 2024-10-28 PlS Planned sale
1.0
Campbell David Alan

President and CEO

Executive Director
11,103 -3.8%
53.94
US$598,909 		11,103 -3.8% 53.94 US$598,909
2024-10-30 2024-10-28 PlS Planned sale
1.0
Campbell David Alan

President and CEO

Executive Director
13,897 -4.5%
53.22
US$739,650 		13,897 -4.5% 53.22 US$739,650
2024-10-28 2024-10-28 PrS Proposed sale
3.9
Reardon Tighe

FORMER OFFICER

Officer
15,122
53.41
US$807,666 		15,122 53.41 US$807,666
2024-10-28 2024-10-28 PrS Proposed sale
4.0
Lichter Jay

FORMER DIRECTOR

Non-Executive Director
3,419
53.51
US$182,954 		3,419 53.51 US$182,954
2024-10-28 2024-10-28 PrS Proposed sale
3.9
Reardon Tighe

Former officer

Officer
9,061
53.36
US$483,520 		9,061 53.36 US$483,520
2024-10-25 2024-10-25 PrS Proposed sale
3.9
Avalon Ventures XI, L.P.

10% Stockholder

Large shareholder
169,320
53.33
US$9,029,544 		169,320 53.33 US$9,029,544
2024-10-25 2024-10-25 PrS Proposed sale
Avalon BioVentures I, LP

10% Stockholder

Large shareholder
32,800
53.33
US$1,749,162 		32,800 53.33 US$1,749,162
2024-10-25 2024-10-25 PrS Proposed sale
Avalon BioVentures SPV I, L.P.

10% Stockholder

Large shareholder
172,880
53.33
US$9,219,392 		172,880 53.33 US$9,219,392
2024-10-25 2024-10-24 PrS Proposed sale
3.9
Reardon Tighe

Former Officer

Officer
21,760
52.80
US$1,148,928 		21,760 52.80 US$1,148,928
2024-10-24 2024-10-24 PrS Proposed sale
4.0
Lichter Jay

FORMER DIRECTOR

Non-Executive Director
4,921
53.37
US$262,653 		4,921 53.37 US$262,653
2024-10-24 2024-10-24 PrS Proposed sale
3.9
Reardon Tighe

FORMER OFFICER

Officer
217,690
5.28
US$1,148,928 		217,690 5.28 US$1,148,928
2024-10-23 2024-10-23 PrS Proposed sale
Avalon BioVentures SPV I, L.P.

10% Stockholder

Large shareholder
248,797
51.23
US$12,745,011 		248,797 51.23 US$12,745,011
2024-10-23 2024-10-23 PrS Proposed sale
Avalon BioVentures I, LP

10% Stockholder

Large shareholder
47,203
51.23
US$2,418,041 		47,203 51.23 US$2,418,041
2024-10-23 2024-10-23 PrS Proposed sale
3.9
Avalon Ventures XI, L.P.

10% Stockholder

Large shareholder
243,672
51.23
US$12,482,475 		243,672 51.23 US$12,482,475
2024-10-23 2024-10-23 PrS Proposed sale
3.9
Reardon Tighe

Former officer

Officer
13,039
51.01
US$665,094 		13,039 51.01 US$665,094
2024-10-21 2024-10-21 PrS Proposed sale
3.9
Reardon Tighe

FORMER OFFICER

Officer
10,769
49.43
US$532,310 		10,769 49.43 US$532,310
2024-10-21 2024-10-21 PrS Proposed sale
4.0
Lichter Jay

FORMER DIRECTOR

Non-Executive Director
2,434
49.49
US$120,454 		2,434 49.49 US$120,454
Explore more

More insider trading research around Janux Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America